The disposition and metabolism of sulphasalazine (salicylazosulphapyridine) in man.

No abstract is available for this paper.

• Publication year

  1982

• Venue

  British Journal of Clinical Pharmacology

• Publication date

  1982-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1111/J.1365-2125.1982.TB01415.XPMID 6121576PMCID PMC1402052
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Is plasma level monitoring of sulfasalazine indicated in the treatment of Crohn's disease or ulcerative colitis?

  1980cited by this paper
• Metabolism and Mode of Action of Sulphasalazine.

  1977cited by this paper
• Determination of salicylazosulphapyridine in biological materials.

  1973cited by this paper
• Distribution studies of salicylazosulfapyridine and its metabolites.

  1973cited by this paper
• Metabolism of salicylazosulfapyridine in healthy subjects and in patients with ulcerative colitis; Effects of colectomy and of phenobarbital

  1973cited by this paper
• Determination of free and acetylated 5-aminosalicylic acid in serum and urine after administration of salicylazosulphapyridine.

  1973cited by this paper
• Determination of sulphapyridine and its metabolites in biological materials after administration of salicylazosulphapyridine.

  1973cited by this paper
• Determination of free and acetylated 5-aminosalicylic acid in serum and urine after administration of salicylazosulphapyridine.

  1973cited by this paper
• The metabolism of salicylazosulphapyridine in ulcerative colitis

  1973cited by this paper
• Absorption, metabolism, and excretion of salicylazosulfapyridine in man

  1972cited by this paper
• Distribution and metabolism of salicyl-azo-sulfapyridine. I. A study with C-14-5-amino-salicylic acid.

  1963cited by this paper

• FATE OF ANTIBIOTICS IN RIVERS RECEIVING TREATED SEWAGE EFFLUENT AND ITS ENVIRONMENTAL RISK ASSESSMENT

  2025cites this paper
• Genetic polymorphisms impacting clinical pharmacology of drugs used to treat inflammatory bowel disease: a precursor to multi-omics approach to precision medicine

  2025cites this paper
• Lung cancer chemo-interception by sulfasalazine and disulfiram co-delivered using a nano self-emulsifying drug delivery system in mice.

  2025cites this paper
• Bacterial Influence on Pharmacokinetics of Tacrolimus and Sulfasalazine through Regulation of Host Metabolism

  2024cites this paper
• Safety assessment of sulfasalazine: a pharmacovigilance study based on FAERS database

  2024cites this paper
• A critical review on formulation and evaluation of colon targeted drug delivery systems

  2023cites this paper
• Synthesis and evaluation of azo pro-drugs of flurbiprofen for colon targeting

  2023cites this paper
• Advances in the implications of the gut microbiota on the treatment efficacy of disease-modifying anti-rheumatic drugs in rheumatoid arthritis

  2023cites this paper
• Efficient colonic drug delivery in domestic pigs employing a tablet formulation with dual control concept.

  2023cites this paper
• Interaction of drugs with gut microbiota modulators

  2023cites this paper
• Managing the clinical effects of drug-induced intestinal dysbiosis with a focus to antibiotics: challenges and opportunities.

  2023cites this paper
• A structural metagenomics pipeline for examining the gut microbiome.

  2022cites this paper
• Induction and application of ferroptosis in cancer therapy

  2022cites this paper
• Tutorial: Microbiome studies in drug metabolism

  2022cites this paper
• Negligible Effect of Quercetin in the Pharmacokinetics of Sulfasalazine in Rats and Beagles: Metabolic Inactivation of the Interaction Potential of Quercetin with BCRP

  2021cites this paper
• Inulin-based carriers for colon drug targeting

  2021cites this paper
• Recent Advances in Prodrug-based Nanoparticle Therapeutics.

  2021cites this paper
• Sulfasalazine alleviates neuropathic pain hypersensitivity in mice through inhibition of SGK-1 in the spinal cord.

  2021cites this paper
• Applications of Polymers in Colon Drug Delivery

  2021cites this paper
• Gut microbiota in reductive drug metabolism.

  2020cites this paper
• Assessment of contribution of BCRP to intestinal absorption of various drugs using portal‐systemic blood concentration difference model in mice

  2020cites this paper
• Behavioral Assessment of Acute Inhibition of System xc-in Rats

  2020cites this paper
• SLC7A11/xCT in cancer: biological functions and therapeutic implications.

  2020cites this paper
• DMARDs–Gut Microbiota Feedback: Implications in the Response to Therapy

  2020cites this paper
• Personalized Mapping of Drug Metabolism by the Human Gut Microbiome.

  2020cites this paper
• The association between NAT2 acetylator status and adverse drug reactions of sulfasalazine: a systematic review and meta-analysis

  2020cites this paper
• Targeting Ferroptosis to Iron Out Cancer.

  2019cites this paper
• Ferroptosis in Cancer Disease

  2019cites this paper
• Systematic mapping of drug metabolism by the human gut microbiome

  2019cites this paper
• Design, synthesis, and in vitro biological evaluation of 14-hydroxytylophorine-dichloroacetate co-drugs as antiproliferative agents.

  2019cites this paper
• The expanding role of prodrugs in contemporary drug design and development

  2018cites this paper
• Drug-microbiota interactions and treatment response: Relevance to rheumatoid arthritis

  2018influential citation
• Controlled-release solid dispersions of Eudragit® FS 100 and poorly soluble spironolactone prepared by electrospinning and melt extrusion

  2017cites this paper
• The microbiome revolution – how can we translate the science into clinical practice?

  2016cites this paper
• Modulation of Apoptosis and Differentiation by the Treatment of Sulfasalazine in Rabbit Articular Chondrocytes

  2016cites this paper
• 5-Aminosalyclic Acid (5-ASA): A Unique Anti-Inflammatory Salicylate

  2016cites this paper
• Therapeutic concentrations of sulfasalazine interfere with ammonia, but not with alanine-aminotransferase determination in enzymatic tests

  2016cites this paper
• ANTIBACTERIAL PREDRUGS-FROM 1899 TILL 2015

  2015cites this paper
• Sulfasalazine in ionic liquid form with improved solubility and exposure

  2015cites this paper
• Colon-Targeted Oral Drug Delivery Systems: Design Trends and Approaches

  2015cites this paper
• Biopharmaceutical considerations and characterizations in development of colon targeted dosage forms for inflammatory bowel disease

  2014cites this paper
• Synthesis , Characterization and Release Studies of Mutual Prodrugs Of Norfloxacin and Trimethoprim With Indomethacin For Colon-Specific Drug Delivery

  2014cites this paper
• Behavioral assessment of acute inhibition of system xc- in rats

  2014cites this paper
• Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis

  2014cites this paper
• On the colonic bacterial metabolism of azo-bonded prodrugsof 5-aminosalicylic acid.

  2014cites this paper
• 5-Aminosalicylate Therapy

  2013cites this paper
• 5-ASA colonic mucosal concentrations resulting from different pharmaceutical formulations in ulcerative colitis.

  2013cites this paper
• Synthesis and quantitative analysis of diastereomeric linked ester conjugates with remote stereocenters using high-field NMR and chiral HPLC.

  2013cites this paper
• COLON TARGETED DRUG DELIVERY SYSTEMS-RECENT UPDATES

  2013cites this paper
• Intestinal targeting of drugs: rational design approaches and challenges.

  2013cites this paper
• Prodrugs Design Based on Inter‐ and Intramolecular Chemical Processes

  2013cites this paper
• [Glutamate and malignant gliomas, from epilepsia to biological aggressiveness: therapeutic implications].

  2013cites this paper
• In Vivo Characterization of Interactions on Transporters

  2013cites this paper
• Drug Delivery: Oral Colon-Specific

  2013cites this paper
• The influence of probiotic treatment on sulfasalazine metabolism in rat

  2012cites this paper
• Metabolism of xenobiotics of human environments.

  2012cites this paper
• Sulfasalazine for brain cancer fits

  2012cites this paper
• Pharmacokinetic interaction study of sulphasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP

  2012influential citation
• Ulcerative Colitis-Associated Colorectal Cancer Prevention by 5-Aminosalicylates: Current Status and Perspectives

  2012cites this paper
• Enzyme‐Activated Prodrug Strategies for Site‐Selective Drug Delivery

  2011cites this paper
• The Gut Microbiota as Target for Innovative Drug Development: Perspectives and a Case Study of Inflammatory Bowel Diseases

  2011cites this paper
• Inhibition of xc⁻ transporter-mediated cystine uptake by sulfasalazine analogs.

  2011cites this paper
• The effects of an orally administered probiotic on sulfasalazine metabolism in individuals with rheumatoid arthritis: a preliminary study

  2010cites this paper
• Report on pharmaceutical approaches to colon targeted drug delivery systems

  2010cites this paper
• Sulfasalazine blocks the release of proteoglycan and collagen from cytokine stimulated cartilage and down-regulates metalloproteinases.

  2009cites this paper
• Biochemical parameters reflecting the intestinal ecology of healthy adults and alterations of these parameters in patients with ulcerative colitis or rheumatoid arthritis

  2009cites this paper
• IMPLICATIONS OF BIODEGRADABLE AND BIOADHESIVE SYSTEMS IN COLON DELIVERY

  2009cites this paper
• Colon-specific mutual amide prodrugs of 4-aminosalicylic acid for their mitigating effect on experimental colitis in rats.

  2009cites this paper
• Evaluation of in vivo dissolution behavior and GI transit of griseofulvin, a BCS class II drug.

  2008cites this paper
• Pharmacogenetic Characterization of Sulfasalazine Disposition Based on NAT2 and ABCG2 (BCRP) Gene Polymorphisms in Humans

  2008cites this paper
• Salazosulphapyridine，Predonizoloneの好中球機能に及ぼす影響とSodium ferrous citrateとの併用効果についての検討

  2007cites this paper
• Effects of Nanocrystalline Silver (NPI 32101) in a Rat Model of Ulcerative Colitis

  2007cites this paper
• Azo compounds in colon-specific drug delivery

  2007cites this paper
• Sodium ferrous citrate

  2006cites this paper
• Molekulare Mechanismen der Gallensäuren-vermittelten Apoptoseinduktion und deren transkriptionelle Modulation in einer humanen Hepatomzelllinie

  2006cites this paper
• Der Einfluß von Sulfasalazin und seiner Metabolite auf die Leukotrien- und Thromboxansynthese in Monozyten und neutrophilen Granulozyten

  2006cites this paper
• Sulfasalazine transport in in‐vitro, ex‐vivo and in‐vivo absorption models: contribution of efflux carriers and their modulation by co‐administration of synthetic nature‐identical fruit extracts

  2005cites this paper
• Charakterisierung der durch hydrophobe Gallensäuren induzierten Leberzellschädigung und deren Modulation durch Phosphatidylinositol-3-Kinasen und Sulfasalazin

  2005cites this paper
• Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs

  2004cites this paper
• Soybean lipoxygenase inhibition: Studies with the sulphasalazine metabolites N-acetylaminosalicylic acid, 5-aminosalicylic acid and sulphapyridine

  2004cites this paper
• Polysaccharides for Colon Targeted Drug Delivery

  2004cites this paper
• Pharmaceutical approaches to colon targeted drug delivery systems.

  2003cites this paper
• The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro‐drugs used in the management of ulcerative colitis

  2003cites this paper
• Analysis and prediction of absorption behavior of colon-targeted prodrug in rats by GI-transit-absorption model.

  2003cites this paper
• 5‐amino‐salicylate in the management of inflammatory bowel disease

  2001cites this paper
• Kinetic phenotypic diagnosis of N-acetylation polymorphism in patients based on ratio of urinary metabolites of salicylazosulfapyridine.

  2001cites this paper
• Bedeutung der Galenik für die luminale Freisetzung von 5-Aminosalicylsäure im menschlichen Dünndarmlumen

  1998cites this paper
• Lower extremity manifestations of nutritional deficiencies in gastrointestinal disease.

  1998cites this paper
• [Significance of galenic preparations for luminal release of 5-aminosalicylic acid in human small intestinal lumen].

  1998cites this paper
• Intestinal fate of 5-aminosalicylic acid: regional and systemic kinetic studies in relation to inflammatory bowel disease.

  1997cites this paper
• Slow-Acting Antirheumatic Drugs

  1995cites this paper
• The Influence of Multiple Oral Doses of Zileuton on the Steady-State Pharmacokinetics of Sulfasalazine and its Metabolites, Sulfapyridine and N-Acetylsulfapyridine

  1995cites this paper
• Oral colon-specific drug delivery: a review

  1995cites this paper
• Biopharmaceutical evaluation of salicylazosulfanilic acid as a novel colon-targeted prodrug of 5-aminosalicylic acid.

  1994cites this paper
• The role of the gastrointestinal microflora in the metabolism of drugs

  1993cites this paper
• Effects of sulphasalazine on lymphocyte functions

  1993cites this paper
• Clinical Pharmacokinetics of Slow-Acting Antirheumatic Drugs

  1993cites this paper
• Review article: the mode of action of the aminosalicylates in inflammatory bowel disease.

  1993cites this paper
• The mode of action of the aminosalicylates in inflammatory bowel disease

  1993cites this paper
• The Effect of Age and Acetylator Phenotype on the Pharmacokinetics of Sulfasalazine in Patients with Rheumatoid Arthritis

  1992cites this paper